Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Thermo Fisher Scientific and Newman-Lakka Institute to Collaborate

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
The collaboration will research diagnostic approaches for personalized cancer treatment.

Thermo Fisher Scientific Inc. and the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center have announced an intended collaboration for research and development of new methods to detect and track circulating biomarkers in blood.

The collaboration will focus on applying Thermo Fisher’s latest ultra-sensitive liquid chromatography-mass spectrometry (LC-MS) instrumentation and technology to develop robust methods for identifying protein biomarkers for a variety of cancers, including breast and prostate cancer as well as tumor-associated blood vessel formation.

“Our challenge and hope is to change the current standard of care, and our collaboration with Thermo Fisher and access to its state-of-the-art instrumentation will accelerate our mission. We hope to be able to provide oncologists with a panel of biomarkers that sense microscopic levels of tumor cells with a simple blood test,” said Charles J. Newman, president of the Newman-Lakka Cancer Foundation.

Newman continued, “The goal is to develop diagnostic tools to make it possible for physicians to check off a panel of biomarkers when patients get regular checkups, so early detection of disease can facilitate effective treatment. Also, the goal is to enable oncologists to monitor the efficacy of treatment with a blood test, rather than waiting 2 months for an MRI and exposing the patients to additional harmful radiation.”

“We’re extremely pleased about this opportunity to collaborate with experts in the search for better cancer treatments,” said Mary Lopez, director of the Thermo Fisher Scientific Biomarkers Research Initiatives in Mass Spectrometry (BRIMS) center that is supporting the collaboration.

Lopez continued, “We anticipate great synergy between Newman-Lakka’s cancer research expertise and our own strength in applying mass spectrometry to biological research and the advancement of personalized medicine will give greater value to both organizations.”

An instrument will be installed at the Genesis Research Institute laboratory adjacent to the Newman Lakka Institute at Tufts Medical Center.

The collaboration’s advanced methods will be conducted at the BRIMS center in Cambridge, Mass., using Thermo Scientific’s triple quadrupole and high resolution accurate mass (HRAM) spectrometry instrumentation, coupled to mass spectrometry immunoassay (MSIA) technology and novel software workflows.

Thermo Fisher’s mass spectrometry instruments are for research use only. Not for use in diagnostic procedures.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Fisher Scientific Chosen for Two Awards
Thermo Scientific Vanquish UHPLC System voted Scientists’ Choice Best New Separations Product, Thermo Fisher Scientific voted Reviewers’ Choice Company of the Year.
Thursday, March 12, 2015
Thermo, University of Birmingham Partner to Study Brominated Flame Retardant Pollution
Research aims to increase understanding of the environmental fate and behavior of brominated persistent organic chemicals through deploying recent advances in analytical instrumentation.
Thursday, August 28, 2014
Thermo Fisher Scientific Signs Distribution Agreement with MKI
The agreement sees Thermo become the exclusive worldwide marketer and distributor of MKI’s Lipid Search software for interpretation of lipidomic research data.
Tuesday, July 09, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Acetaldehyde and Formaldehyde Content in Foods
Korean researchers have determined the content of the toxic and carcinogenic aldehydes, acetaldehyde and formaldehyde, in a variety of food groups.
Combining the Power of Mass Spectrometry & Microscopy
A tool that provides world-class microscopy and spatially resolved chemical analysis shows considerable promise for advancing a number of areas of study, including chemical science, pharmaceutical development and disease progression.
Advancing Lithium-Ion Battery Research
The increasing number of components in a lithium-ion battery makes it essential to use a variety of analytical methods to attain complete characterization.
Fruit Fly Pheromone Flags Great Real Estate for Starting a Family
Finding could aid efforts to control mosquito-borne diseases like malaria by manipulating odorants
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos